Best of the Week
Most Popular
1. TESLA! Cathy Wood ARK Funds Bubble BURSTS! - 12th May 21
2.Stock Market Entering Early Summer Correction Trend Forecast - 10th May 21
3.GOLD GDX, HUI Stocks - Will Paradise Turn into a Dystopia? - 11th May 21
4.Crypto Bubble Bursts! Nicehash Suspends Coinbase Withdrawals, Bitcoin, Ethereum Bear Market Begins - 16th May 21
5.Crypto Bubble BURSTS! BTC, ETH, XRP CRASH! NiceHash Seizes Funds on Account Halting ALL Withdrawals! - 19th May 21
6.Cathy Wood Ark Invest Funds Bubble BURSTS! ARKK, ARKG, Tesla Entering Severe Bear Market - 13th May 21
7.Stock Market - Should You Be In Cash Right Now? - 17th May 21
8.Gold to Benefit from Mounting US Debt Pile - 14th May 21
9.Coronavius Covid-19 in Italy in August 2019! - 13th May 21
10.How to Invest in HIGH RISK Tech Stocks for 2021 and Beyond - Part 2 of 2 - 18th May 21
Last 7 days
WESTERN DIGITAL WDC Stock Trend Analysis - CHIA! - Risk 1 - 23rd Jun 21
AMC Is the Best-Performing Stock in America: Don’t Buy It - 23rd Jun 21
Stock Market Calling the Fed‘s Bluff - 23rd Jun 21
Could Bitcoin Price CRASH Target A Bottom Below $7500? - 23rd Jun 21
Bitcoin and cryptos: Your 'long-term investment'? - 23rd Jun 21
Unlocking The Next Stage Of The Hydrogen Boom - 23rd Jun 21
USDT Ponzi Scheme FINAL WARNING To EXIT Before Tether Collapses Crypto Exchange Markets - 22nd Jun 21
Stock Market Correction Starting - 22nd Jun 21
This Green SuperFuel Could Change Everything For the $14 Trillion Shipping Industry - 22nd Jun 21
Virgin Media Fibre Broadband Installation - What to Expect, Quality of Wiring, Service etc. - 21st Jun 21
Feel the Inflationary Heartbeat - 21st Jun 21
The Green Superfuel That Could Disrupt Global Energy Markers - 21st Jun 21
How Binance SCAMs Crypto Traders with UP DOWN Coins, Futures, Options and Leverage - Don't Get Bogdanoffed! - 20th Jun 21
Smart Money Accumulating Physical Silver Ahead Of New Basel III Regulations And Price Explosion To $44 - 20th Jun 21
Rambling Fed Triggers Gold/Silver Correction: Are Investors Being Duped? - 20th Jun 21
Gold: The Fed Wreaked Havoc on the Precious Metals - 20th Jun 21
Investing in the Tulip Crypto Mania 2021 - 19th Jun 21
Here’s Why Historic US Housing Market Boom Can Continue - 19th Jun 21
Cryptos: What the "Bizarre" World of Non-Fungible Tokens May Be Signaling - 19th Jun 21
Hyperinflationary Expectations: Reflections on Cryptocurrency and the Markets - 19th Jun 21
Gold Prices Investors beat Central Banks and Jewelry, as having the most Impact - 18th Jun 21
Has the Dust Settled After Fed Day? Not Just Yet - 18th Jun 21
Gold Asks: Will the Economic Boom Continue? - 18th Jun 21
STABLE COINS PONZI Crypto SCAM WARNING! Iron Titan CRASH to ZERO! Exit USDT While You Can! - 18th Jun 21
FOMC Surprise Takeaways - 18th Jun 21
Youtube Upload Stuck at 0% QUICK FIXES Solutions Tutorial - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations Video - 18th Jun 21
AI Stock Buying Levels, Ratings, Valuations and Trend Analysis into Market Correction - 17th Jun 21
Stocks, Gold, Silver Markets Inflation Tipping Point - 17th Jun 21
Letting Yourself Relax with Activities That You Might Not Have Considered - 17th Jun 21
RAMPANT MONEY PRINTING INFLATION BIG PICTURE! - 16th Jun 21
The Federal Reserve and Inflation - 16th Jun 21
Inflation Soars 5%! Will Gold Skyrocket? - 16th Jun 21
Stock Market Sentiment Speaks: Inflation Is For Fools - 16th Jun 21
Four News Events That Could Drive Gold Bullion Demand - 16th Jun 21
5 ways that crypto is changing the face of online casinos - 16th Jun 21
Transitory Inflation Debate - 15th Jun 21
USDX: The Cleanest Shirt Among the Dirty Laundry - 15th Jun 21
Inflation and Stock Market SPX Record Highs. PPI, FOMC Meeting in Focus - 15th Jun 21
Stock Market SPX 4310 Right Around the Corner! - 15th Jun 21
AI Stocks Strength vs Weakness - Why Selling Google or Facebook is a Big Mistake! - 14th Jun 21
The Bitcoin Crime Wave Hits - 14th Jun 21
Gold Time for Consolidation and Lower Volatility - 14th Jun 21
More Banks & Investors Are NOT Believing Fed Propaganda - 14th Jun 21
Market Inflation Bets – Squaring or Not - 14th Jun 21
Is Gold Really an Inflation Hedge? - 14th Jun 21
The FED Holds the Market. How Long Will It Last? - 14th Jun 21
Coinbase vs Binance for Bitcoin, Ethereum Crypto Trading & Investing During Bear Market 2021 - 11th Jun 21
Gold Price $4000 – Insurance, A Hedge, An Investment - 11th Jun 21
What Drives Gold Prices? (Don't Say "the Fed!") - 11th Jun 21
Why You Need to Buy and Hold Gold Now - 11th Jun 21
Big Pharma Is Back! Biotech Skyrockets On Biogen’s New Alzheimer Drug Approval - 11th Jun 21
Top 5 AI Tech Stocks Trend Analysis, Buying Levels, Ratings and Valuations - 10th Jun 21
Gold’s Inflation Utility - 10th Jun 21
The Fuel Of The Future That’s 9 Times More Efficient Than Lithium - 10th Jun 21
Challenges facing the law industry in 2021 - 10th Jun 21
SELL USDT Tether Before Ponzi Scheme Implodes Triggering 90% Bitcoin CRASH in Cryptos Lehman Bros - 9th Jun 21
Stock Market Sentiment Speaks: Prepare For Volatility - 9th Jun 21
Gold Mining Stocks: Which Door Will Investors Choose? - 9th Jun 21
Fed ‘Taper’ Talk Is Back: Will a Tantrum Follow? - 9th Jun 21
Scientists Discover New Renewable Fuel 3 Times More Powerful Than Gasoline - 9th Jun 21
How do I Choose an Online Trading Broker? - 9th Jun 21
Fed’s Tools are Broken - 8th Jun 21
Stock Market Approaching an Intermediate peak! - 8th Jun 21
Could This Household Chemical Become The Superfuel Of The Future? - 8th Jun 21
The Return of Inflation. Can Gold Withstand the Dark Side? - 7th Jun 21
Why "Trouble is Brewing" for the U.S. Housing Market - 7th Jun 21
Stock Market Volatility Crash Course (VIX vs VVIX) – Learn How to Profit From Volatility - 7th Jun 21
Computer Vision Is Like Investing in the Internet in the ‘90s - 7th Jun 21
MAPLINS - Sheffield Down Memory Lane, Before the Shop Closed its Doors for the Last Time - 7th Jun 21
Wire Brush vs Block Paving Driveway Weeds - How Much Work, Nest Way to Kill Weeds? - 7th Jun 21
When Markets Get Scared and Reverse - 7th Jun 21
Is A New Superfuel About To Take Over Energy Markets? - 7th Jun 21

Market Oracle FREE Newsletter

How to Protect your Wealth by Investing in AI Tech Stocks

Cutting Through the Biotech Stocks Hype

Companies / BioTech Dec 04, 2013 - 05:39 PM GMT

By: Investment_U

Companies

Marc Lichtenfeld: When a woman, claiming to be the wife of a deceased general from Nigeria, writes to us saying she needs our help getting $10 million out of the country and in return we’ll get 20% of the money, most of us know that’s a load of bull.

But when the CEO of a publicly traded biotech company tells us his drug is the next great thing? How do we know if he’s being truthful, hopeful or just a plain scam artist?


All stocks, especially those in the biotech sector, are susceptible to overhype, which leads to disappointed investors.

I’ve had my share of winners and losers over the years and have dealt with all kinds of companies. As a result, I believe my B.S. detector is pretty sensitive. Let me help you fine-tune yours.

When evaluating biotech companies, consider:

1. What kind of language does the company use?
Do its press releases sound like hype? Most reputable, science-driven companies won’t use words like “stunning” or promote that something it accomplished has never been achieved before. Its language will be more guarded.

Additionally, what does the CEO say? When discussing the effectiveness of his company’s melanoma drug, Synta Pharmaceuticals (Nasdaq: SNTA) CEO Dr. Safi Bahcall once told me, “It’s either water or it’s not water. And we know it’s not water.”

He was right. It wasn’t water. But it wasn’t medicine, either. The Phase 3 trial was stopped early because the death rate among patients taking the drug was significantly higher than those who did not receive it.

I compare that to the conversations I’ve had with the management team from Compugen (Nasdaq: CGEN), whose stock spiked 45% in August on news of a collaboration with Bayer. It’s gained another 30% since.

I’ve spoken with management many times, and while Chairman Martin Gerstel is an enthusiastic supporter and spokesman for the company, I’ve never once heard him make a promise that his company’s technology will lead to marketable drugs.

He certainly thinks it will, but that’s a big difference between claiming it will and making sure investors understand there is still work to be done before anything is proven.

Additionally, Gerstel already made his fortune selling his former firm, Alza, to Johnson & Johnson (NYSE: JNJ) for $10.5 billion. He doesn’t need to spend his time and energy on making money. He’s in it to try to change the way medicine is developed.

Some quick research on an executive’s background may shed some light on their motivation for getting involved with a particular company.

2. Are trials placebo-controlled and double-blinded?
When a company runs late-stage clinical trials, particularly for cancer, you want the trials to be randomized, placebo-controlled, double-blinded trials. That means neither the patient nor the doctor knows if the experimental drug or placebo is being delivered. (In cancer cases, the placebo is whatever drugs are considered the standard of care, as it would be immoral to not treat a cancer patient.)

Not knowing which drug is being taken is important to avoid a placebo effect – where a patient might feel better or a doctor might look for data points that suggest the patient is recovering based on the belief that the new drug is effective.

Additionally, by comparing the drug being studied to a placebo or standard of care, the evidence of whether it is safe and effective should be clearer than when it is simply being studied alone.

Sometimes, for various reasons, a double-blinded, placebo-controlled study isn’t feasible. But usually it is. If a company is running a Phase 3 trial that is open label (everyone knows that the patient is receiving the drug) and you can’t find a valid reason for it – run, don’t walk, away from the stock.

3. How many patients?
Sometimes, a company will proudly announce the results of a clinical trial. In cancer drugs a 30% response rate can be enough to get approved by the FDA. But if, in a clinical trial, a company announces 12 out of 30 patients responded to the drug, that’s not exactly an impressive sample size.

Of course, if it’s an earlier stage study, the trial did exactly what it’s supposed to, which is to determine if the drug is worth being developed further. But a company that is hyping the results based on a small number of patients is more interested in promoting its stock than good science.

Not to pick on Synta again, but it recently issued a press release saying that four out of 15 breast cancer patients saw tumor shrinkage when taking its drug ganetespib. That’s great. The problem is the study was supposed to enroll 70 patients.

So why is the company releasing data on just 15? It’s not like all 15 had a response rate. That would have been newsworthy. The recent data was not. So why did it release it early?

4. Who is promoting the stock?
Do you ever get those promotions that tell you why a stock is going to skyrocket? If the company names the stock in the promotion, read the small print very carefully. There’s a good chance the firm hired a stock promoter – which is usually a pump and dumper.

A company can get a large amount of shares or cash (or both) in return for promoting the stock to retail investors. While those investors are buying, the promoter and company insiders are selling.

Never buy a stock that you learn about in a promotion if the fine print says that the promoter has been compensated for sending you the information.

Keep in mind that Investment U and The Oxford Club do not accept or receive compensation from companies for writing about individual stocks, funds or any other kind of investments.

Investing in biotech stocks can be incredibly rewarding. But because these stocks can fly so quickly, there are people out there trying to help them take off, whether the science justifies it or not. It’s in your best interest to be able to discern whether the CEO or other spokesperson is sensible or a hype artist.

Good investing,

Marc

Source: http://www.investmentu.com/2013/December/cutting-through-the-hype-in-biotech.html

http://www.investmentu.com

Copyright © 1999 - 2013 by The Oxford Club, L.L.C All Rights Reserved. Protected by copyright laws of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), of content from this website, in whole or in part, is strictly prohibited without the express written permission of Investment U, Attn: Member Services , 105 West Monument Street, Baltimore, MD 21201 Email: CustomerService@InvestmentU.com

Disclaimer: Investment U Disclaimer: Nothing published by Investment U should be considered personalized investment advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized investment advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers. All of our employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of printed-only publication prior to following an initial recommendation. Any investments recommended by Investment U should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company.

Investment U Archive

© 2005-2019 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in